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Abstract
This paper presents a review of established and emerging methods for detecting and quantifying the intravenous anaesthetic 
propofol in solution. There is growing evidence of numerous advantages of total intravenous anaesthesia using propofol 
compared to conventional volatile-based anaesthesia, both in terms of patient outcomes and environmental impact. However, 
volatile-based anaesthesia still accounts for the vast majority of administered general anaesthetics, largely due to a lack of 
techniques for real-time monitoring of patient blood propofol concentration. Herein, propofol detection techniques that have 
been developed to date are reviewed alongside a discussion of remaining challenges.
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1 Introduction
Propofol (2,6-diisopropylphenol) is an intravenous drug 
used for the induction and maintenance of anaesthesia. It 
has favourable characteristics, including rapid induction and 
a short half-life, and consequently it has been the most com-
monly used intravenous anaesthetic for the last 30 years [1, 
2].
Until recently, the most common practice in general 
anaesthesia was to use an intravenous anaesthetic, such as 
propofol, for the induction phase and volatile anaesthetics 
for the maintenance phase [3]. However, it is possible to use 
propofol for both the induction and maintenance phases, in 
a process known as total intravenous anaesthesia (TIVA). 
There is a growing body of evidence of the advantages of 
TIVA over the more conventional volatile-based anaesthe-
sia, including: reduced short-term side-effects [3], reduced 
cognitive effects [4–6], the potential for improved long-term 
survival rates for cancer patients [7, 8], and a significantly 
reduced environmental impact [9–11].
Despite these numerous advantages, conventional vol-
atile-based anaesthesia still accounts for the vast majority 
of administered general anaesthetics world-wide [3]. One 
significant obstacle to a greater exploitation of TIVA is the 
lack of suitable methods for the continuous, real-time moni-
toring of blood propofol concentration in patients undergo-
ing anaesthesia.
This paper presents a review of solution-phase propofol 
detection techniques and their potential application to real-
time propofol monitoring. To the authors’ knowledge this 
represents the first review of propofol detection. There are 
also researchers who have investigated monitoring propofol 
in exhaled breath [3, 12–14]. However, as the relationship 
between blood propofol concentration and exhaled breath 
concentration is not fully understood [15], it remains unclear 
whether this approach will be applicable to patient moni-
toring; and gaseous propofol detection techniques will not 
therefore be covered in this review.
2  Detection methods
2.1  Chromatography
High performance liquid chromatography (HPLC) is perhaps 
the most commonly reported method for the detection and 
quantification of propofol, and considered by many to be the 
‘gold standard’ for validation purposes. HPLC may be used 
in conjunction with a variety of measurement techniques, 
with the most common being fluorometric detection.
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When using fluorometric detection, the most common 
excitation and emission wavelengths are 276 nm and 310 nm 
respectively [16–19], however, the use of other wavelengths 
has been reported [20]. Typically, the mobile phases consist 
of mixtures of either methanol [16] or acetonitrile [17, 18] 
with water. Nishio et al. have demonstrated propofol detec-
tion using fluorometric-HPLC using only water as a mobile 
phase by utilising a temperature-responsive polymer as a 
stationary phase [19]. Fluorometric-HPLC has been demon-
strated for the detection of propofol from serum and whole 
blood samples, with the samples being pre-treated either 
by precipitation of proteins using acetonitrile [16–18] or by 
solid phase extraction [19]. Reported limits of quantification 
range between 3 and 400 ng/ml [17, 18], with linear ranges 
typically extending up to the order of 10 μg/ml.
Another common measurement technique used in con-
junction with HPLC is UV photometry. Absorbance is 
measured at wavelengths ranging from 210 to 280 nm [21, 
22] and the mobile phases typically consist of acetonitrile 
mixed with either an acidic buffer [21, 23] or ammonium 
[22]. Reported linear regions range from the order of 10 to 
100 μg/ml and limits of quantification as low as 20 ng/ml 
have been reported [23].
The use of electrochemical measurement in conjunction 
with HPLC has also been reported, although this approach 
appears less common. Dowrie et al. have reported elec-
trochemical detection of propofol from human serum 
and plasma using a mixture of methanol and an acidic 
buffer for the mobile phase and a measurement potential 
of + 0.8 V [24]. This group reports a linear range of 0.01 
to 1 μg/ml. Pissinis et al. have utilised a highly alkaline 
mobile phase as at a higher pH propofol will be ionised 
and therefore oxidation can be carried out at a lower 
potential (ca. + 0.1 V), resulting in reduced interference 
[25]. Using this method, they report a limit of detection 
of 5 ng/ml. A summary of HPLC-based propofol detection 
techniques is presented in Table 1.
Whilst it may be a ubiquitous technique, HPLC is not 
well suited to point-of-care applications due to its reliance 
on bulky and expensive equipment. Furthermore, HPLC 
offers only discrete, rather than continuous measurement. 
It also requires complex and time-consuming sample pre-
treatment methods.
Mass spectrometry is another common technique for 
the detection and quantification of propofol in biological 
samples, in conjunction with either gas chromatography 
[26–28] or liquid chromatography [29–32]. As for HPLC, 
when analysing propofol in whole blood, serum or plasma, 
the propofol is extracted from the sample either by solvent 
[26, 27] or solid phase extraction [29, 31].
Gas chromatography-mass spectrometry (GC–MS) has 
been demonstrated to be capable of detecting propofol in 
blood samples with lower limits between 2.5 and 10 ng/
ml [26, 27], with linear ranges between 0.01 and 10 μg/ml. 
Similar values have been reported for liquid chromatogra-
phy tandem mass spectrometry (LC–MS/MS) [29, 31, 32] 
although Vaiano et al. have reported a detection limit of 
0.1 ng/ml from whole blood using this technique [33]. A 
summary of mass spectrometry-based propofol detection 
techniques is presented in Table 2.
As for HPLC, the principle disadvantages of mass spec-
trometry techniques are the requirement for expensive and 
bulky equipment and the lack of capacity for continuous 
monitoring. A particular drawback is the requirement for 
lengthy analysis and sample preparation processes, with 
one group reporting analysis times of 40 min and sample 
preparation times of 300 min [28].
Table 1  Summary of reported HPLC propofol detection and quantification techniques
NR not reported
a Where a limit of detection (LoD) is stated in preference to a limit of quantification (LoQ), LoQ is assumed to be three times LoD
Measurement Mobile phase Extraction LoQa (ng/ml) Range (μg/ml) References
Fluorescent Methanol/water Acetonitrile 50 1–10 [16]
Fluorescent Acetonitrile/water/trifluoroacetic acid Acetonitrile 400 0.4–40 [17]
Fluorescent Acetonitrile/water Acetonitrile 3 0.05–10 [18]
Fluorescent Water Solid-phase NR 0.5–10 [19]
Fluorescent Methanol/phosphate buffer (pH 4.5) Methanol 100 0.1–3 [20]
UV Acetonitrile/buffer (pH 2.5) NR 750 15–75 [21]
UV Acetonitrile/ammonium NR NR 37–592 [22]
UV Acetonitrile/buffer (pH 3) Solid-phase 20 NR [23]
Electrochemical Methanol/phosphate buffer (pH 2.8) Pentane 5 0.01–1 [24]
Electrochemical Acetonitrile/buffer NR 15 NR [25]
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2.2  Optical techniques
To achieve the spectrophotometric detection of propofol, 
many groups have taken advantage of the Gibbs reaction. 
This is the name given to the process wherein 2,6-dichloro-
quinone-4-chlorimide (DCQ), also known as Gibbs’ reagent, 
reacts with phenolic compounds in alkaline conditions to 
produce an indophenol (Fig. 1) [34, 35]. This indophenol 
will be a blue-to-violet coloured species with an absorption 
maximum of approximately 600 nm.
Gad-Kariem and Abounassif have exploited this reac-
tion to demonstrate the detection of propofol in biological 
fluids by mixing samples with DCQ solution, dimethyl sul-
foxide and a buffer (pH 9.6), allowing the mixture to react 
for 15 min and then measuring the absorbance at 635 nm 
[36]. By this method this group were able to demonstrate 
the detection of propofol in spiked plasma and urine with 
a linear range of 1–5 μg/ml and a detection limit in plasma 
of 0.28 μg/ml.
Hong et al. have also made use of the Gibbs reaction [37]. 
This group have developed a disposable microfluidic chip 
containing a molecularly imprinted polymer (MIP) for the 
solid phase extraction of propofol. The MIP film is synthe-
sised by the UV-initiated co-polymerisation of methacrylic 
acid and ethylene glycol dimethacrylate. The chip is used in 
conjunction with a laser diode and photodetector to meas-
ure the absorbance of the MIP at 655 nm, after mixing the 
analyte solution with DCQ within the microfluidic device. 
In this manner this group has demonstrated the detection of 
propofol in methanol solution across the range 0.25 to 10 μg/
ml. It is reported that this set-up returns the propofol con-
centration within 60 s. However, the device cannot accom-
modate whole blood and this timeframe does not include the 
sample preparation time that would be required if working 
with blood, serum or plasma.
Liu et al. have also demonstrated the spectrophotomet-
ric detection of propofol by exploiting the Gibbs reaction 
[38]. This group have used the Pelorus 1000 system (Sphere 
Medical Ltd.). In this system a 0.7 ml sample of whole blood 
is diluted and the red blood cells lysed. Propofol is then 
extracted from the lysed blood by solid phase extraction 
and reacted with DCQ. The resultant indophenol is then 
detected via colourimetry. Using this system, the authors 
reported a limit of quantification for propofol in whole blood 
of 0.75 μg/ml with a linear response up to 12 μg/ml. It is 
reported that the time-to-results is approximately 5 min and 
that no sample preparation, beyond that performed automati-
cally by the system, is required. This same system has been 
used to measure the blood propofol concentration of ponies 
under anaesthesia [39].
Sramkova et  al. have demonstrated an alternative 
approach for the spectrophotometric detection of propofol 
[40]. In this method, propofol is oxidised in the presence of 
hydrogen peroxide in a reaction catalysed by the enzyme 
Table 2  Summary of reported 
mass spectrometry propofol 
detection and quantification 
techniques
a Where a limit of detection (LoD) is stated in preference to a limit of quantification (LoQ), LoQ is assumed 
to be three times LoD
NR not reported
Technique Extraction LoQa (ng/ml) Range (μg/ml) References
GC–MS Chloroform–ethyl acetate 10 0.01–10 [26]
GC–MS Heptane 7.5 0.01–5 [27]
GC–MS Ethyl acetate 325 NR [28]
GC–MS Dichloromethane/ethyl acetate 5 NR [33]
LC–MS/MS Solid-phase 5 0.005–2 [29]
LC–MS/MS Acetone NR 0.02–20 [30]
LC–MS/MS Solid-phase NR 0.01–1.5 [31]
LC–MS/MS Methanol–acetonitrile/solid-phase 10 0.01–10 [32]
LC–MS/MS Dichloromethane/ethyl acetate 0.1 NR [33]
Fig. 1  Gibbs reaction for propo-
fol. Propofol reacts with DCQ 
to produce a coloured indophe-
nol. Adapted from Mistry et al. 
[35]
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horseradish peroxidase (HRP). The product of this reac-
tion is then coupled with 4-aminoantipyrine, producing a 
coloured solution, the absorbance of which is measured at 
485 nm. By this method the authors report a propofol detec-
tion limit of 1.6 μg/ml with a linear range of 5 to 100 μg/ml. 
However, this approach was developed for the determina-
tion of propofol concentrations within commercial propofol 
emulsions, rather than within biological fluids. This same 
group compared the above method with a fluorometric 
method. By measuring the fluorescent emission of propofol 
at 347 nm in ethanol, they were able to detect propofol with 
a limit of detection of 1.3 μg/ml and a linear range of 4 to 
243 μg/ml.
Li et al. have also utilised fluorescence spectroscopy for 
propofol detection [41]. Using an optical fibre with an on-
line MIP for solid phase extraction, they have demonstrated 
propofol detection in whole blood with two distinct linear 
ranges between 0.1 and 15 μg/ml. These two linear regions 
are the result of two different types of binding site within the 
MIP. The authors report a time-to-results of 5 min.
This same group has also used a similar optical fibre 
to detect propofol via spectrophotometry. By reacting 
propofol with a diazonium salt, a coloured product can be 
formed with an absorption peak at 483 nm. In this manner 
the authors have demonstrated the detection of propofol in 
plasma samples across a linear range of 3 to 18 μg/ml [42]. 
Additionally, this group has developed a technique exploit-
ing graphene quantum dots for the detection of propofol via 
fluorescence photometry. In the presence of the enzyme 
HRP and hydrogen peroxide, propofol will be oxidised to 
form 2,6-diisopropylquinone. This quinone will quench the 
natural fluorescence of the quantum dots, allowing for the 
detection of propofol to a limit of 0.5 μg/ml with a linear 
range of 5.34 to 89.07 μg/ml. This method was developed 
for the detection of propofol in emulsions [43].
El Sharkasy et al. have developed a method for the simul-
taneous detection of propofol and cisatracurium (a muscle 
relaxant commonly co-administered with propofol) by deriv-
ative synchronous spectrofluorometry [44]. By analysing the 
first derivative spectra at 279.6 nm, this group were able to 
demonstrate the detection of propofol in spiked serum sam-
ples across a linear range of 40 to 400 ng/ml with a detection 
limit of 4 ng/ml. No indication is given as to the reporting 
time of this technique, although when detecting propofol in 
human serum the authors employed a protein precipitation 
technique that requires tens of minutes to perform. A sum-
mary of reported optical propofol detection techniques is 
presented in Table 3.
2.3  Electrochemical techniques
It is possible to detect propofol by electrochemical tech-
niques [24, 25, 45]. However, it is well documented that 
the electrochemical oxidisation of propofol will result in 
the deposition of an insoluble polymer film on the elec-
trode resulting in the rapid passivation (or fouling) of the 
electrode surface [46–51]. The group of Lindner et al. have 
shown that propofol can be detected using stripping vol-
tammetry, but that the electrode needs to be replaced or 
freshly polished after each measurement [45]. The same 
group have also reported that propofol can be detected 
without electrode fouling by using a restricted potential 
window. However, this approach results in a problematic 
lack of specificity. In order to address these issues, this 
group have developed a technique whereby electrodes are 
coated with a plasticised polyvinyl chloride (PVC) mem-
brane which prevents electrode fouling, improves selectiv-
ity and lowers the limit of detection [2, 52, 53]. Propofol 
is highly lipophilic, and therefore it will be present in the 
organic membrane at a far higher concentration than an 
aqueous medium. Commonly interfering compounds are 
more hydrophilic, and will hence be less preferentially 
absorbed into the film. Using this technique, this group 
have demonstrated chronoamperometric detection of 
Table 3  Summary of reported 
optical propofol detection and 
quantification techniques
NR not reported
a Where a limit of detection (LoD) is stated in preference to a limit of quantification (LoQ), LoQ is assumed 
to be three times LoD
Technique LoQa (μg/ml) Range (μg/ml) References
Spectrophotometry (Gibbs) 0.84 1–5 [36]
Spectrophotometry (Gibbs/MIP) 0.75 0.25–10 [37]
Spectrophotometry (Gibbs) 0.75 0.75–12 [38]
Spectrophotometry (HRP) 5.3 5–100 [40]
Spectrophotometry (diazonium salt) 2.14 3–18 [42]
Fluorometry 4.3 4–243 [40]
Fluorometry (MIP) NR 0.1–15 [41]
Fluorometry (quantum dots) 1.5 5.34–89.07 [43]
Derivative synchronous spectrofluorometry 0.0121 0.04–0.4 [44]
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propofol using both glassy carbon and gold electrodes. 
They have reported a limit of detection of approximately 
14 ng/ml, a linear range up to approximately 3.5 μg/ml 
and have demonstrated the detection of propofol in spiked 
human serum. One issue regarding PVC membranes is 
whether they possess physical and mechanical properties 
suitable for long-term, continuous usage [54]. This group 
have demonstrated these sensors for up to three hours of 
continuous use.
Hong et al. have addressed the selectivity issues by the 
application of a MIP [55] (this same group’s application 
of MIPs to optical propofol detection was outlined in the 
preceding section). They have developed a propofol specific 
MIP based on the conductive polymer polypyrrole, which 
is electropolymerised upon gold interdigitated electrodes. 
The binding of propofol to this MIP results in changes to the 
surface electrical properties, leading to a drop in the conduc-
tivity (Fig. 2). In this manner, this group has demonstrated 
a disposable biochip for chemiresistive propofol detection. 
The authors report a limit of detection of 0.1 μg/ml with a 
linear range of 0.1 to 30 μg/ml and a time-to-results of 25 s. 
However, continuous measurement has not yet been demon-
strated. Additionally, with MIP sensors there is a possibility 
of slow mass transfer of the analyte to the active sites, if the 
pore-size distribution is heterogeneous, which is undesirable 
for long-term, continuous propofol monitoring [56].
Stradolini et al. have demonstrated a technique where 
the fouling of the electrode during propofol detection is 
mitigated by the inclusion of periodic electrode cleaning 
steps [15]. Using either boron doped diamond or pencil 
graphite electrodes, this group were able to demonstrate 
the continuous voltammetric monitoring of propofol in 
serum over 4 h by intermittently performing either a cyclic 
voltammetry-based cleaning procedure in sodium hydrox-
ide or a chronoamperometry-based cleaning procedure in 
phosphate buffered saline. However, it is unclear how practi-
cal these cleaning steps would prove in the context of real-
world propofol monitoring during general anaesthesia. This 
group reports a limit of detection of approximately 0.42 μg/
ml using cyclic voltammetry. A summary of reported elec-
trochemical propofol detection techniques is presented in 
Table 4.
3  Challenges and future prospects
The aim of delivering real-time monitoring of blood propo-
fol concentration during general anaesthesia places a number 
of requirements on any potential propofol sensing technique. 
For instance, any method must be capable of returning 
results within a sufficiently narrow window of time to pro-
vide information that is of practical use to anaesthetists or 
Fig. 2  Representation of the binding of propofol molecules to a conductive molecularly imprinted polymer (MIP) and the associated equivalent 
circuit diagram. Reprinted with permission [55] Copyright Elsevier 2016
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other healthcare professionals. This is a major reason why 
approaches such as HPLC and mass spectrometry, which 
have a time-to-results of the order of several tens of minutes 
at best [28], are of limited utility for this application. Meth-
ods that require non-trivial sample pre-treatment will likely 
not be suitable for this same reason, and as such, sensors 
capable of functioning at physiological conditions will likely 
be more suitable than those that are not (for instance opti-
cal techniques based on the Gibbs reaction, which requires 
alkaline conditions [36–38]).
There are examples of groups who have reported the 
detection of propofol in urine as well as blood [28, 36]. How-
ever, due to the significant time-lag between administering a 
drug and it or its metabolites presenting in a patient’s urine, 
this approach will not be applicable to real-time propofol 
monitoring during general anaesthesia. Whole blood, serum 
or plasma represent the most practical biological fluids for 
this application.
To be of use for patient monitoring in a surgical context, 
any sensor system would need to be capable of producing 
stable results over the duration of a surgical procedure, 
potentially 8 h or longer. Furthermore, it has been shown 
that propofol will slowly redistribute between the plasma 
and blood cell membranes over time [57], meaning that the 
time between the collection and measurement of a sample 
will need to be tightly controlled. As such, any technique for 
real-time propofol monitoring must be suitable for automa-
tion, with minimal sample processing.
It is likely during general anaesthesia that propofol will 
be co-administered with other drugs, and as such it is neces-
sary that any propofol sensor possess a sufficient degree of 
specificity. The Gibbs reagent will react with any phenolic 
molecule, so any optical detection technique based on the 
Gibbs reaction may face specificity issues if any co-admin-
istered drugs contain phenol groups. Approaches based on 
similar colourimetric techniques will face similar issues. 
Likewise, any fluorometric approach will need to ensure 
that there are no interfering compounds with overlapping 
excitation or emission windows. Specificity will also be a 
particular challenge for electrochemical approaches as the 
potential window in which propofol is electrochemically 
oxidised corresponds to the electroactive window for many 
potential interfering compounds [53].
One potential approach to improving the specificity of 
propofol sensors is the use of MIPs [37, 42, 55]. However, 
MIPs possess a finite number of binding sites and there-
fore may suffer from saturation effects over long timescales. 
Additionally, as discussed previously, there is the potential 
for slow mass transfer [56]. Another potential approach for 
improving the specificity of propofol sensors are membrane 
coated electrodes such as those developed by Linder et al. [2, 
52, 53]. However, the performance of such electrodes over 
time periods of several hours has yet to be fully investigated.
When demonstrating propofol detection in plasma, serum 
or whole blood, the groups discussed in Sects. 2.2 and 2.3 
mostly make use of spiked samples rather than real samples 
from patients or animals who have been administered propo-
fol. It is known that approximately 98% of the blood concen-
tration of propofol is bound, either to erythrocytes or serum 
proteins, with only the remaining 2% existing free in solu-
tion [58]; the latter free-fraction most likely being the phar-
macologically active drug. Therefore, it is unclear how rep-
resentative spiked samples will prove, particularly in cases 
such as MIPs or membrane coated electrodes where protein 
binding may hinder the transport of the propofol molecules 
to the sensor surface. Any real-time propofol detection tech-
nique intended for use with whole blood, serum or plasma 
will either need to be capable of detecting both bound and 
unbound propofol or to be capable of detecting propofol in 
concentration ranges up to two orders of magnitude lower 
than the therapeutic range (typically 0.25–10 μg/ml [52]). 
Few of the emerging technologies discussed in this review 
have sensitivities even approaching this range.
Future work in this field is likely to be focussed upon 
achieving the required sensitivities for the detection of the 
free-fraction of propofol in blood and demonstrating the 
required specificity to reliably differentiate propofol from 
potential interfering compounds. This work will be coupled 
with efforts to integrate such sensors with automated sample 
collection and processing technologies in order to achieve 
the real-time monitoring of blood propofol concentration 
that is required for the monitoring of patients undergoing 
general anaesthesia.
4  Concluding remarks
Despite increasing evidence of the many advantages of 
TIVA compared to conventional volatile-based anaesthe-
sia, both in terms of patient outcomes and environmental 
impact, TIVA still only accounts for a small percentage of 
administered general anaesthetics worldwide. The principle 
Table 4  Summary of reported electrochemical propofol detection and 
quantification techniques
NR not reported
a Where a limit of detection (LoD) is stated in preference to a limit of 
quantification (LoQ), LoQ is assumed to be three times LoD
b Converted from μM
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obstacle to a more widespread use of TIVA is the lack of 
suitable methods for monitoring a patient’s blood propofol 
concentration in real time. Existing methods such as HPLC 
and mass spectroscopy are too complex, expensive and slow 
to return results. In recent years there has been much pro-
gress in emerging propofol sensing techniques, consisting 
of both optical and electrochemical approaches. However, 
many challenges still remain, particularly in terms of sensi-
tivity and sensor lifetime.
Electrochemical approaches are attractive due to their 
potential for high sensitivity and ease of automation, but 
possess significant challenges in terms of specificity and the 
potential for electrode fouling. In contrast, optical techniques 
generally require a greater degree of sample preparation and 
have not yet been demonstrated to be as suitable for continu-
ous measurement.
Future work in this area will likely focus on improve-
ments to sensitivity and specificity and on integrating sen-
sors into technologies to enable automated and continuous 
measurement.
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